PCRX
Pacira BioSciences, Inc.
Price Chart
Latest Quote
$22.71
+0.38 (+1.70%)
Current Price
| Previous Close | $22.33 |
| Open | $22.21 |
| Day High | $22.84 |
| Day Low | $22.00 |
| Volume | 656,878 |
Stock Information
| Shares Outstanding | 39.35M |
| Total Debt | $411.18M |
| Cash Equivalents | $202.18M |
| Revenue | $734.86M |
| Net Income | $5.14M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $893.59M |
| P/E Ratio | 174.69 |
| EPS (TTM) | $0.13 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.09B |
| Sales | $734.86M |
| Income | $5.14M |
| Book/sh | $16.63 |
| Cash/sh | $5.14 |
| Employees | 825 |
Financial Ratios
| Quick Ratio | 3.01 |
| Current Ratio | 4.73 |
| Debt/Eq | 62.88 |
| EPS Growth TTM | -39.40% |
Returns & Margins
| ROA | 1.35% |
| ROE | 0.71% |
| Gross Margin | 79.33% |
| Operating Margin | 2.61% |
| Profit Margin | 0.70% |
Ownership
| Insider Ownership | 1.77% |
| Institutional Ownership | 115.42% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 6.23 |
| PEG | 11.21 |
| P/S | 1.22 |
| P/B | 1.37 |
Analyst Data
| Recommendation | buy |
| Target Price | $29.67 |
Technical Indicators
| SMA20 | $23.03 |
| SMA50 | $23.61 |
| SMA200 | $23.48 |
| RSI | 46.44 |
| ATR | 0.7675 |
| Shares Float | 33.72M |
| Short Float | 24.24% |
| Short Ratio | 10.76 |
| Volatility | 0.29 |
| Rel Volume | 1.44 |
Performance History
| Week | -1.22% |
| Month | -1.26% |
| Quarter | +2.71% |
| 6 Months | -14.46% |
| YTD | -7.15% |
| Year | -5.96% |
| 3 Years | -41.38% |
| 5 Years | -62.16% |
| 10 Years | -43.21% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $22.71 | 666,719 |
| 2026-06-18 | $22.33 | 951,000 |
| 2026-06-17 | $22.64 | 342,300 |
| 2026-06-16 | $22.82 | 546,800 |
| 2026-06-15 | $22.74 | 350,800 |
| 2026-06-12 | $22.99 | 371,200 |
| 2026-06-11 | $23.36 | 395,700 |
| 2026-06-10 | $23.42 | 275,900 |
| 2026-06-09 | $23.21 | 412,700 |
| 2026-06-08 | $22.86 | 386,700 |
| 2026-06-05 | $22.75 | 402,700 |
| 2026-06-04 | $22.67 | 518,300 |
| 2026-06-03 | $22.32 | 244,900 |
| 2026-06-02 | $22.25 | 345,400 |
| 2026-06-01 | $22.96 | 482,800 |
| 2026-05-29 | $23.22 | 511,500 |
| 2026-05-28 | $23.68 | 243,000 |
| 2026-05-27 | $24.04 | 303,700 |
| 2026-05-26 | $24.36 | 635,900 |
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
đ° Latest News
Considering Pacira Biosciences Inc (PCRX) Stock After Q1 Report? Check the Details
Insider Monkey âĸ 2026-05-27T21:18:51Z
Doma Perpetual Buys Another $5.6 Million of Nomad Foods With the Stock Down 20% in 2026
Motley Fool âĸ 2026-05-21T15:37:08Z
Pacira BioSciences' (NASDAQ:PCRX) Performance Is Even Better Than Its Earnings Suggest
Simply Wall St. âĸ 2026-05-13T18:59:45Z
Assessing Pacira BioSciences (PCRX) Valuation After Earnings Update And New EXPAREL Real World Data
Simply Wall St. âĸ 2026-05-03T09:11:26Z
Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
Zacks âĸ 2026-05-01T17:24:00Z
Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release
Motley Fool âĸ 2026-05-01T12:37:10Z
Pacira BioSciences Inc (PCRX) Q1 2026 Earnings Call Highlights: Strong Product Growth Amidst ...
GuruFocus.com âĸ 2026-05-01T07:18:05ZPacira BioSciences Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-01T01:41:05Z
Pacira BioSciences, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-01T00:46:53Z
Pacira (PCRX) Q1 2026 Earnings Call Transcript
Motley Fool âĸ 2026-04-30T23:23:32Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $116,014,000 | $148,931,000 | $166,383,000 | $165,082,000 |
| Cost Of Revenue | $149,749,000 | $170,428,000 | $184,669,000 | $199,295,000 |
| Total Revenue | $726,411,000 | $700,966,000 | $674,978,000 | $666,823,000 |
| Operating Revenue | $726,411,000 | $700,966,000 | $674,978,000 | $666,823,000 |
| Expenses | ||||
| Interest Expense | $14,606,000 | $13,439,000 | $17,310,000 | $35,576,000 |
| Total Expenses | $707,220,000 | $611,094,000 | $587,303,000 | $606,799,000 |
| Other Income Expense | $-7,603,000 | $-156,098,000 | $-17,112,000 | $-11,288,000 |
| Other Non Operating Income Expenses | $-6,620,000 | $-373,000 | $-186,000 | $-11,288,000 |
| Net Non Operating Interest Income Expense | $5,286,000 | $3,120,000 | $-8,862,000 | $-35,434,000 |
| Total Other Finance Cost | $2,840,000 | $3,130,000 | $2,996,000 | $4,400,000 |
| Interest Expense Non Operating | $14,606,000 | $13,439,000 | $17,310,000 | $35,576,000 |
| Operating Expense | $557,471,000 | $440,666,000 | $402,634,000 | $407,504,000 |
| Other Operating Expenses | $14,112,000 | $7,702,000 | $-352,000 | $10,903,000 |
| Selling And Marketing Expense | $226,616,000 | $172,015,000 | $153,040,000 | $144,996,000 |
| General And Administrative Expense | $142,143,000 | $122,084,000 | $116,401,000 | $109,520,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $7,034,000 | $-99,560,000 | $41,955,000 | $15,909,000 |
| Net Interest Income | $5,286,000 | $3,120,000 | $-8,862,000 | $-35,434,000 |
| Interest Income | $22,732,000 | $19,689,000 | $11,444,000 | $4,542,000 |
| Normalized Income | $7,810,570 | $23,462,750 | $53,464,680 | $15,909,000 |
| Net Income From Continuing And Discontinued Operation | $7,034,000 | $-99,560,000 | $41,955,000 | $15,909,000 |
| Total Operating Income As Reported | $19,191,000 | $-73,371,000 | $87,675,000 | $60,024,000 |
| Average Dilution Earnings | $0 | $0 | $4,114,000 | $0 |
| Net Income Common Stockholders | $7,034,000 | $-99,560,000 | $41,955,000 | $15,909,000 |
| Net Income | $7,034,000 | $-99,560,000 | $41,955,000 | $15,909,000 |
| Net Income Including Noncontrolling Interests | $7,034,000 | $-99,560,000 | $41,955,000 | $15,909,000 |
| Net Income Continuous Operations | $7,034,000 | $-99,560,000 | $41,955,000 | $15,909,000 |
| Pretax Income | $16,874,000 | $-63,106,000 | $61,701,000 | $13,302,000 |
| Special Income Charges | $-983,000 | $-155,725,000 | $-16,926,000 | $0 |
| Interest Income Non Operating | $22,732,000 | $19,689,000 | $11,444,000 | $4,542,000 |
| Operating Income | $19,191,000 | $89,872,000 | $87,675,000 | $60,024,000 |
| Depreciation Amortization Depletion Income Statement | $57,288,000 | $57,288,000 | $57,288,000 | $57,288,000 |
| Depreciation And Amortization In Income Statement | $57,288,000 | $57,288,000 | $57,288,000 | $57,288,000 |
| Amortization Of Intangibles Income Statement | $57,288,000 | $57,288,000 | $57,288,000 | $57,288,000 |
| Gross Profit | $576,662,000 | $530,538,000 | $490,309,000 | $467,528,000 |
| Per Share | ||||
| Diluted EPS | $0.16 | $-2.15 | $0.89 | $0.34 |
| Basic EPS | $0.16 | $-2.15 | $0.91 | $0.35 |
| Other | ||||
| Tax Effect Of Unusual Items | $-206,430 | $-32,702,250 | $-5,416,320 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $123,486,000 | $184,843,000 | $171,511,000 | $140,379,000 |
| Total Unusual Items | $-983,000 | $-155,725,000 | $-16,926,000 | $0 |
| Total Unusual Items Excluding Goodwill | $-983,000 | $-155,725,000 | $-16,926,000 | $0 |
| Reconciled Depreciation | $91,023,000 | $78,785,000 | $75,574,000 | $91,501,000 |
| EBITDA (Bullshit earnings) | $122,503,000 | $29,118,000 | $154,585,000 | $140,379,000 |
| EBIT | $31,480,000 | $-49,667,000 | $79,011,000 | $48,878,000 |
| Diluted Average Shares | $45,042,000 | $46,245,000 | $51,979,000 | $46,538,000 |
| Basic Average Shares | $44,566,000 | $46,245,000 | $46,222,000 | $45,521,000 |
| Diluted NI Availto Com Stockholders | $7,034,000 | $-99,560,000 | $46,069,000 | $15,909,000 |
| Tax Provision | $9,840,000 | $36,454,000 | $19,746,000 | $-2,607,000 |
| Other Special Charges | $983,000 | $-7,518,000 | $16,926,000 | - |
| Impairment Of Capital Assets | $0 | $163,243,000 | $0 | $0 |
| Restructuring And Mergern Acquisition | $14,112,000 | $7,702,000 | $-352,000 | $10,903,000 |
| Amortization | $57,288,000 | $57,288,000 | $57,288,000 | $57,288,000 |
| Research And Development | $117,312,000 | $81,577,000 | $76,257,000 | $84,797,000 |
| Selling General And Administration | $368,759,000 | $294,099,000 | $269,441,000 | $254,516,000 |
| Other Gand A | $100,277,000 | $87,227,000 | $82,737,000 | $73,989,000 |
| Salaries And Wages | $41,866,000 | $34,857,000 | $33,664,000 | $35,531,000 |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $304,797,000 | $352,378,000 | $223,629,000 | $71,221,000 |
| Total Assets | $1,264,917,000 | $1,553,516,000 | $1,574,386,000 | $1,681,200,000 |
| Total Non Current Assets | $716,943,000 | $808,386,000 | $1,064,392,000 | $1,182,866,000 |
| Other Non Current Assets | $22,308,000 | $35,649,000 | $36,049,000 | $27,170,000 |
| Non Current Deferred Assets | $123,854,000 | $130,376,000 | $144,485,000 | $160,309,000 |
| Non Current Deferred Taxes Assets | $123,854,000 | $130,376,000 | $144,485,000 | $160,309,000 |
| Goodwill And Other Intangible Assets | $388,314,000 | $425,970,000 | $646,501,000 | $703,789,000 |
| Other Intangible Assets | $368,100,000 | $425,970,000 | $483,258,000 | $540,546,000 |
| Current Assets | $547,974,000 | $745,130,000 | $509,994,000 | $498,334,000 |
| Other Current Assets | $32,618,000 | $21,929,000 | $21,504,000 | $15,223,000 |
| Inventory | $152,863,000 | $125,282,000 | $104,353,000 | $96,063,000 |
| Receivables | $124,069,000 | $113,304,000 | $105,556,000 | $98,397,000 |
| Accounts Receivable | $124,069,000 | $113,304,000 | $105,556,000 | $98,397,000 |
| Cash Cash Equivalents And Short Term Investments | $238,424,000 | $484,615,000 | $278,581,000 | $288,651,000 |
| Cash And Cash Equivalents | $158,545,000 | $276,774,000 | $153,298,000 | $104,139,000 |
| Investmentin Financial Assets | - | $0 | $2,410,000 | $37,209,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $213,644,000 | $308,547,000 | $369,139,000 | $585,332,000 |
| Total Debt | $418,204,000 | $638,853,000 | $586,044,000 | $763,394,000 |
| Long Term Debt And Capital Lease Obligation | $408,365,000 | $428,190,000 | $568,602,000 | $720,625,000 |
| Long Term Debt | $372,189,000 | $383,545,000 | $513,796,000 | $655,823,000 |
| Current Debt And Capital Lease Obligation | $9,839,000 | $210,663,000 | $17,442,000 | $42,769,000 |
| Current Debt | - | $201,776,000 | $8,641,000 | $33,648,000 |
| Other Current Borrowings | - | $201,776,000 | $8,641,000 | $33,648,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $571,806,000 | $775,168,000 | $704,256,000 | $906,190,000 |
| Total Non Current Liabilities Net Minority Interest | $451,216,000 | $465,248,000 | $606,873,000 | $758,416,000 |
| Other Non Current Liabilities | $38,638,000 | $37,058,000 | $38,271,000 | $37,791,000 |
| Non Current Deferred Liabilities | $4,213,000 | $0 | - | - |
| Non Current Deferred Taxes Liabilities | $4,213,000 | $0 | - | - |
| Current Liabilities | $120,590,000 | $309,920,000 | $97,383,000 | $147,774,000 |
| Payables And Accrued Expenses | $72,910,000 | $70,446,000 | $58,259,000 | $78,807,000 |
| Interest Payable | $782,000 | $1,418,000 | $1,389,000 | $8,941,000 |
| Payables | $15,150,000 | $19,133,000 | $15,698,000 | $15,220,000 |
| Accounts Payable | $15,150,000 | $19,133,000 | $15,698,000 | $15,220,000 |
| Total Tax Payable | - | - | - | $0 |
| Income Tax Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $693,111,000 | $778,348,000 | $870,130,000 | $775,010,000 |
| Total Equity Gross Minority Interest | $693,111,000 | $778,348,000 | $870,130,000 | $775,010,000 |
| Stockholders Equity | $693,111,000 | $778,348,000 | $870,130,000 | $775,010,000 |
| Gains Losses Not Affecting Retained Earnings | $4,327,000 | $343,000 | $247,000 | $-380,000 |
| Other Equity Adjustments | $4,327,000 | $343,000 | $247,000 | $-380,000 |
| Retained Earnings | $-199,322,000 | $-206,356,000 | $-106,796,000 | $-148,751,000 |
| Other | ||||
| Treasury Shares Number | $6,774,038 | $837,240 | - | - |
| Ordinary Shares Number | $41,116,739 | $46,240,604 | $46,481,174 | $45,927,790 |
| Share Issued | $47,890,777 | $47,077,844 | $46,481,174 | $45,927,790 |
| Tangible Book Value | $304,797,000 | $352,378,000 | $223,629,000 | $71,221,000 |
| Invested Capital | $1,065,300,000 | $1,363,669,000 | $1,392,567,000 | $1,464,481,000 |
| Working Capital | $427,384,000 | $435,210,000 | $412,611,000 | $350,560,000 |
| Capital Lease Obligations | $46,015,000 | $53,532,000 | $63,607,000 | $73,923,000 |
| Total Capitalization | $1,065,300,000 | $1,161,893,000 | $1,383,926,000 | $1,430,833,000 |
| Treasury Stock | $176,565,000 | $25,121,000 | $0 | - |
| Additional Paid In Capital | $1,064,623,000 | $1,009,435,000 | $976,633,000 | $924,095,000 |
| Capital Stock | $48,000 | $47,000 | $46,000 | $46,000 |
| Common Stock | $48,000 | $47,000 | $46,000 | $46,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $36,176,000 | $44,645,000 | $54,806,000 | $64,802,000 |
| Current Capital Lease Obligation | $9,839,000 | $8,887,000 | $8,801,000 | $9,121,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $37,841,000 | $28,811,000 | $21,682,000 | $26,198,000 |
| Current Accrued Expenses | $57,760,000 | $51,313,000 | $42,561,000 | $63,587,000 |
| Goodwill | $20,214,000 | $0 | $163,243,000 | $163,243,000 |
| Net PPE | $182,467,000 | $216,391,000 | $234,947,000 | $254,389,000 |
| Accumulated Depreciation | $-137,703,000 | $-132,929,000 | $-135,306,000 | $-117,480,000 |
| Gross PPE | $320,170,000 | $349,320,000 | $370,253,000 | $371,869,000 |
| Leases | $77,450,000 | $86,034,000 | $61,826,000 | $61,302,000 |
| Construction In Progress | $9,485,000 | $27,996,000 | $105,905,000 | $103,226,000 |
| Other Properties | $41,777,000 | $49,222,000 | $61,020,000 | $70,877,000 |
| Machinery Furniture Equipment | $191,458,000 | $186,068,000 | $141,502,000 | $136,464,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $81,327,000 | $47,098,000 | $19,039,000 | $27,400,000 |
| Work In Process | $28,201,000 | $27,384,000 | $31,215,000 | $28,853,000 |
| Raw Materials | $43,335,000 | $50,800,000 | $54,099,000 | $39,810,000 |
| Other Short Term Investments | $79,879,000 | $207,841,000 | $125,283,000 | $184,512,000 |
| Investments And Advances | - | $0 | $2,410,000 | $37,209,000 |
| Available For Sale Securities | - | - | $2,410,000 | $37,209,000 |
| Other Investments | - | - | - | $27,170,000 |
| Non Current Deferred Revenue | - | - | - | - |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $136,661,000 | $178,753,000 | $139,488,000 | $115,198,000 |
| Operating Activities | ||||
| Operating Cash Flow | $151,994,000 | $189,389,000 | $154,649,000 | $145,274,000 |
| Cash Flow From Continuing Operating Activities | $151,994,000 | $189,389,000 | $154,649,000 | $145,274,000 |
| Operating Gains Losses | $983,000 | $-7,518,000 | $16,926,000 | $285,000 |
| Investing Activities | ||||
| Capital Expenditure | $-15,333,000 | $-10,636,000 | $-15,161,000 | $-30,076,000 |
| Investing Cash Flow | $99,481,000 | $-83,276,000 | $77,541,000 | $-225,185,000 |
| Cash Flow From Continuing Investing Activities | $99,481,000 | $-83,276,000 | $77,541,000 | $-225,185,000 |
| Net Other Investing Changes | - | - | - | $-32,000,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-148,328,000 | $-25,000,000 | $0 | $0 |
| Financing Cash Flow | $-369,627,000 | $17,363,000 | $-183,031,000 | $-401,528,000 |
| Cash Flow From Continuing Financing Activities | $-369,627,000 | $17,363,000 | $-183,031,000 | $-401,528,000 |
| Net Other Financing Charges | $-7,803,000 | $-9,841,000 | $-7,019,000 | $-1,175,000 |
| Net Common Stock Issuance | $-148,328,000 | $-25,000,000 | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-317,799,000 | $-210,885,000 | $-330,312,000 | $-427,694,000 |
| Issuance Of Debt | $101,000,000 | $287,500,000 | $149,550,000 | $0 |
| Interest Paid Supplemental Data | $15,235,000 | $15,418,000 | $27,635,000 | $33,295,000 |
| End Cash Position | $158,545,000 | $276,774,000 | $153,298,000 | $104,139,000 |
| Beginning Cash Position | $276,774,000 | $153,298,000 | $104,139,000 | $585,578,000 |
| Effect Of Exchange Rate Changes | $-77,000 | $0 | $0 | - |
| Changes In Cash | $-118,152,000 | $123,476,000 | $49,159,000 | $-481,439,000 |
| Proceeds From Stock Option Exercised | $3,303,000 | $-24,411,000 | $4,750,000 | $27,341,000 |
| Common Stock Payments | $-148,328,000 | $-25,000,000 | $0 | $0 |
| Net Issuance Payments Of Debt | $-216,799,000 | $76,615,000 | $-180,762,000 | $-427,694,000 |
| Net Long Term Debt Issuance | $-216,799,000 | $76,615,000 | $-180,762,000 | $-427,694,000 |
| Long Term Debt Payments | $-317,799,000 | $-210,885,000 | $-330,312,000 | $-427,694,000 |
| Long Term Debt Issuance | $101,000,000 | $287,500,000 | $149,550,000 | $0 |
| Net Investment Purchase And Sale | $131,516,000 | $-72,640,000 | $92,702,000 | $-163,109,000 |
| Sale Of Investment | $273,807,000 | $179,572,000 | $237,068,000 | $237,576,000 |
| Purchase Of Investment | $-142,291,000 | $-252,212,000 | $-144,366,000 | $-400,685,000 |
| Net Business Purchase And Sale | $-16,702,000 | $0 | $0 | $-32,000,000 |
| Purchase Of Business | $-16,702,000 | $0 | $0 | $-32,000,000 |
| Net PPE Purchase And Sale | $-15,333,000 | $-10,636,000 | $-15,161,000 | $-30,076,000 |
| Purchase Of PPE | $-15,333,000 | $-10,636,000 | $-15,161,000 | $-30,076,000 |
| Change In Working Capital | $-38,266,000 | $-11,098,000 | $-41,201,000 | $-16,433,000 |
| Change In Payables And Accrued Expense | $1,255,000 | $17,518,000 | $-20,689,000 | $-13,585,000 |
| Change In Accrued Expense | $6,853,000 | $14,434,000 | $-21,605,000 | $-19,857,000 |
| Change In Payable | $-5,598,000 | $3,084,000 | $916,000 | $6,272,000 |
| Change In Account Payable | $-5,598,000 | $3,084,000 | $916,000 | $6,272,000 |
| Change In Prepaid Assets | $-1,212,000 | $61,000 | $-5,063,000 | $-2,699,000 |
| Change In Inventory | $-27,567,000 | $-20,929,000 | $-8,290,000 | $2,486,000 |
| Change In Receivables | $-10,742,000 | $-7,748,000 | $-7,159,000 | $-2,079,000 |
| Changes In Account Receivables | $-10,742,000 | $-7,748,000 | $-7,159,000 | $-2,079,000 |
| Other Non Cash Items | $-9,625,000 | $-6,255,000 | $-2,115,000 | $-21,984,000 |
| Stock Based Compensation | $57,502,000 | $51,171,000 | $47,895,000 | $48,092,000 |
| Asset Impairment Charge | $36,866,000 | $163,243,000 | $0 | $36,134,000 |
| Deferred Tax | $6,477,000 | $20,621,000 | $15,615,000 | $-7,945,000 |
| Deferred Income Tax | $6,477,000 | $20,621,000 | $15,615,000 | $-7,945,000 |
| Depreciation Amortization Depletion | $91,023,000 | $78,785,000 | $75,574,000 | $91,501,000 |
| Depreciation And Amortization | $91,023,000 | $78,785,000 | $75,574,000 | $91,501,000 |
| Net Income From Continuing Operations | $7,034,000 | $-99,560,000 | $41,955,000 | $15,909,000 |
| Income Tax Paid Supplemental Data | - | $11,021,000 | $4,366,000 | $7,398,000 |
| Change In Other Current Liabilities | - | $2,714,000 | $434,000 | $-556,000 |
| Gain Loss On Investment Securities | - | - | - | $92,000 |
| Gain Loss On Sale Of PPE | - | - | - | $193,000 |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Issuance | - | - | - | - |
| Change In Other Working Capital | - | - | - | - |
Fetched: 2026-06-21